Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

Moreover, recent studies have reported that the preservation of GFR is an important predictor of survival in human CHF.

The researchers hypothesized that the acute detrimental renal hemodynamic and tubular responses to furosemide in symptomatic human CHF will be attenuated by AT(1) receptor blockade with losartan.

Who Took Part

The study group was 10 subjects.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the subjects nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

Each person switched between Angiotensin II and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Aldosterone, Angiotensin II, Angiotensin Receptor Antagonists, Diuretics, Furosemide, Glomerular Filtration Rate and Heart Failure.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 10 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2003 (American journal of physiology. Renal physiology), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.